Innate swaps its lead candidate for Astra’s Lumoxiti in a bid to become a rare cancer player.
As data on Amicus Therapeutics' clinical-stage Pompe disease candidate roll in, the group locks up preclinical gene therapy assets.
The company’s plan to cut jobs and look at external deals could be a sign that it is becoming more like other big pharmas.
A genome editing tie-up between Gilead and Precision Biosciences, and promising early data with Arrowhead’s RNA interference project, are two novel approaches in hep B.
Since becoming a pure-play health tech group Philips has been buying like crazy. Might Siemens Healthineers and GE Healthcare join in?
Immunocore has recently been beset with multiple senior executive departures, but has managed to press on into phase I with a Glaxo-partnered asset.
The Danish company’s latest deal covers glucose-sensitive insulin, which could avoid hypoglycaemia in type 2 diabetes patients.
The two companies disagree on the commercial potential of an mRNA flu vaccine, and Biontech just got Pfizer’s buy-in.
Novo Nordisk's cell therapy collaborations are a sign that serious work is under way.